Please assess the completion status of the following clinical trial:

Trial Title: EUS-guided Laser Ablation in Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of pancreatic ductal adenocarcinoma~* Unresectable advanced, non-metastatic Stage III tumor~* Stable disease without regression or progression after 6 months of chemotherapeutic treatment~* Locally progressive disease after chemiotherapy, without evidence of metastases~* Age \>18 and \<80 years~* Willing to be followed up c/o the Fondazione Policlinico A. Gemelli University Hospital~* Signed informed consent~Exclusion Criteria:~* Stage I, Stage II, Stage IV disease~* Absolute contraindications to general anesthesia or deep sedation~* Absolute contraindications to perform digestive endoscopy~* Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh frozen plasma (FFP)~* Use of anticoagulants that cannot be discontinued~* International Normalized Ratio (INR) \>1.5 or platelet count \<50.000~* Pregnancy or lactation~* Unable to sigh informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EUS-guided laser ablation (Type: EXPERIMENTAL): Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.

Based on this trial design, predict the completion outcome and termination type (if applicable).